The USA-based company launched in October 2022 with $125 million in financing, including a $90 million Series A. The firm aims to use the financing to advance its pipeline programs, including its lead program, NEST-1, a non-degrading, molecular glue that targets multiple critical components in the RAS/MAPK pathway.
Nested is focused on discovering and developing next generation precision oncology small molecule medicines. It is advancing drug discovery programs based on a platform that combines insights in cancer biology, structural biology, biophysics and chemical biology to identify innovative strategies to target cancer genes.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze